Mechanisms of liver injury relevant to pediatric hepatology

Critical Reviews in Clinical Laboratory Sciences

Volumn 39, Issue 1, 2002, Pages 1-61

  Tanner, M S ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; AUTOIMMUNE HEPATITIS; CELL DEATH; CHOLESTASIS; ENDOPLASMIC RETICULUM; FAMILIAL DISEASE; GLYCOSYLATION; HUMAN; HUMAN CELL; LIVER BLOOD FLOW; LIVER INJURY; LIVER PROTECTION; PATHOGENESIS; PEDIATRICS; PRIORITY JOURNAL; REVIEW; SEPSIS; STELLATE CELL;

AUTOIMMUNE DISEASES; HEPATITIS B; HEPATITIS C; HUMANS; INFANT; INFANT, NEWBORN; LIVER; LIVER DISEASES; PEDIATRICS;

ANIMALIA;

EID: 0036186543     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408360290795439     Document Type: Review

References (263)

1. Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients
2. Alagille syndrome. The widening spectrum of arteriohepatic dysplasia
3. Caroli's disease diagnosed in a child by MRCP
4. Caroli's syndrome in a 1-year-old child
5. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis
6. Carbon monoxide and sepsis: Is a toxic gas good for your liver?
7. Nitric oxide and hepatic ischemia-reperfusion injury
8. Carbon monoxide: An endogenous modulator of sinusoidal tone in the perfused rat liver
9. Carbon monoxide as a regulator of bile canalicular contractility in cultured rat hepatocytes
10. Zonation of parenchymal and nonparenchymal metabolism in liver
11. Oxygen: Modulator of metabolic zonation and disease of the liver
12. Apoptosis in diseases of the liver
13. Apoptosis and liver diseases: Recent concepts of mechanism and significance
14. Recognizing death: Liver phagocytosis of apoptotic cells
15. Lethal effect of the anti-Fas antibody in mice
16. The hepatic stellate (Ito) cell: Its role in human liver disease
17. Hepatic stellate (ITO) cells: Expanding roles for a liver-specific pericyte
18. The cell biology of liver fibrogenesis - An imbalance of proliferation, growth arrest and apoptosis of myofibroblasts
19. Na+/H+ exchange and growth factor-induced cytosolic pH changes. Role in cellular proliferation
20. Rat liver myofibroblasts and hepatic stellate cells: Different cell populations of the fibroblast lineage with fibrogenic potential
21. In situ expression of fibrogenic growth factors and their receptors in biliary atresia: Comparison between early and late stages
22. Nitric oxide in liver injury
23. Modulation of the mitochondrial permeability transition by nitric oxide
24. Mechanisms of nitric oxide-dependent apoptosis: Involvement of mitochondrial mediators
25. Nitric oxide induces apoptosis via triggering mitochondrial permeability transition
26. Western blot analysis for nitrotyrosine protein adducts in livers of saline-treated and acetaminophen-treated mice
27. Mechanisms of hepatic toxicity. I. TNF-induced liver injury
28. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
29. The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release
30. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure
31. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death
32. Reactive oxygen and mechanisms of inflammatory liver injury
33. Liver complications of pediatric parenteral nutrition - Epidemiology
34. Staphylococcal enterotoxin B potentiates LPS-induced hepatic dysfunction in chronically catheterized rats
35. The hepatic microvascular responses to sepsis
36. The role of chemokines in the immunopathology of the liver
37. Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in TNFa-induced liver injury
38. Mechanisms of neutrophil-induced parenchymal cell injury
39. Pathophysiological roles of interleukin-18 in inflammatory liver diseases
40. The liver as a crucial organ in the first line of host defense: The roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses
41. Identification of the gene that, when mutated, causes the human obesity syndrome BBS4
42. Early-onset liver disease complicated with acute liver failure in Alstrom syndrome
43. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13
44. Hepatic steatosis: Innocent bystander or guilty party?
45. Liver morphology in morbid obesity: A literature study
46. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease
47. Nonalcoholic steatohepatitis in children
48. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis
49. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis
50. Prognostic indicators of hepatic injury following jejunoileal bypass performed for refractory obesity: A prospective study
51. The use of donor fatty liver for liver transplantation: A challenge or a quagmire?
52. Mitochondrial abnormalities in non-alcoholic steatohepatitis
53. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
54. Free fatty acid effects on mitochondrial permeability: An overview
55. Palmitic acid opens a novel cyclosporin A-insensitive pore in the inner mitochondrial membrane
56. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
57. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis
58. Troglitazone-associated hepatic failure
59. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus
60. Metabolic and nutritional considerations in nonalcoholic fatty liver
61. Aflatoxin excretion in children with kwashiorkor or marasmic kwashiorkor - A clinical investigation
62. Aflatoxin exposure and its relationship to kwashiorkor in African children
63. Aflatoxin and kwashiorkor
64. Autoimmune hepatitis
65. Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors
66. Genetically determined low C4: A predisposing factor to autoimmune chronic active hepatitis
67. Polymorphism in the human complement C4 genes and genetic susceptibility to autoimmune hepatitis
68. Autoimmune chronic active hepatitis in a family
69. Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis
70. Primary and secondary liver/kidney microsomal autoantibody response following infection with hepatitis C virus
71. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance
72. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals
73. Autoantibodies in liver disease
74. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis
75. A novel assay for detecting antibodies to cytochrome P4502D6, the molecular target of liver kidney microsomal antibody type 1
76. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis
77. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane
78. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid- induced hepatitis
79. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D
80. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis
81. Soluble liver antigen: Isolation of a 35-kd recombinant protein (SLA- p35) specifically recognizing sera from patients with autoimmune hepatitis
82. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis
83. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion
84. A bioinformatical approach suggests the function of the autoimmune hepatitis target antigen soluble liver antigen/liver pancreas
85. Lessons about antibodies in autoimmune hepatitis
86. The dynamics of the immune response in acute hepatitis B: New lessons using new techniques
87. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection
88. Hepatitis B virus transgenic mice: Models of viral immunobiology and pathogenesis
89. H-2(d) mice born to and reared by HBeAg-transgenic mothers do not develop T cell tolerance toward the hepatitis B virus core gene products
90. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence
91. Hepatitis C: The clinical spectrum of disease
92. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
93. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules
94. Liver-derived CTL in hepatitis C virus infection: Breadth and specificity of responses in a cohort of persons with chronic infection
95. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children
96. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: A nested case-control study of the Dionysos cohort
97. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
98. Clinical significance of hepatitis C virus genotypes and quasispecies
99. Analysis of a successful immune response against hepatitis C virus
100. Analysis of successful immune responses in persons infected with hepatitis C virus
101. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase
102. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: Model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease
103. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism
104. Genetic variability in susceptibility and response to toxicants
105. Role of biotransformation in conceptal toxicity of drugs and other chemicals
106. Normal thymic architecture and negative selection are associated with Aire expression, the gene defective in the autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
107. Mutations in the AIRE gene: Effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein
108. Isolation and characterization of the mouse Aire gene
109. The APECED polyglandular autoimmune syndrome protein, AIRE-1, contains the SAND domain and is probably a transcription factor
110. The autoimmune regulator protein has transcriptional transactivating properties and interacts with the common coactivator CREB-binding protein
111. Lafora disease: A progressive myoclonus epilepsy
112. Lafora's disease: Towards a clinical, pathologic, and molecular synthesis
113. Folding of secretory and membrane proteins
114. Heteropolymerization of S, I, and Z alphal-antitrypsin and liver cirrhosis
115. Alphal-antitrypsin deficiency: From genotype to childhood disease
116. Protein misfolding and degradation in genetic diseases
117. A kinetic mechanism for the polymerization of alphal-antitrypsin
118. Pathogenic alpha 1-antitrypsin polymers are formed by reactive loop- beta-sheet A linkage
119. Prospective study of children with alpha 1-antitrypsin deficiency: Eight-year-old follow-up
120. The liver in adolescents with alpha 1-antitrypsin deficiency
121. Severe pancreatitis and fatty liver progressing to cirrhosis associated with Coxsackie B4 infection in a three year old with alpha-1- antitrypsin deficiency
122. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency
123. The Niemann-Pick C lesion and its relationship to the intracellular distribution and utilization of LDL cholesterol
124. Cessation of rapid late endosomal tubulovesicular trafficking in Niemann-Pick type C1 disease
125. Depletion of rafts in late endocytic membranes is controlled by NPC1- dependent recycling of cholesterol to the plasma membrane
126. Dynamic movements of organelles containing niemann-pick c 1 protein: npc 1 involvement in late endocytic events
127. Genotype-phenotype relationship of Niemann-Pick disease type C: A possible correlation between clinical onset and levels of NPC1 protein in isolated skin fibroblasts
128. Evidence for a Niemann-pick C (NPC) gene family: Identification and characterization of NPC1L1
129. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient
130. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice
131. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I
132. Genetic control of morphogenetic and biochemical differentiation: Lethal albino deletions in the mouse
133. In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I
134. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors
135. Deficient DNA-ligase activity in the metabolic disease tyrosinemia type I
136. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
137. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione)
138. Fumarylacetoacetase mutations in tyrosinaemia type I
139. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes
140. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I
141. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo
142. Komrower Lecture. Galactosaemia today: The enigma and the challenge
143. Galactose metabolism in mice with galactose-1-phosphate uridyltransferase deficiency: Sucklings and 7-week-old animals fed a high-galactose diet
144. Disorders of fructose metabolism
145. Metabolic depletion of ATP by fructose inversely controls CD95- and tumor necrosis factor receptor 1-mediated hepatic apoptosis
146. Simple, rapid non-radioactive method to detect the three most prevalent hereditary fructose intolerance mutations
147. Neonatal screening for hereditary fructose intolerance: Frequency of the most common mutant aldolase B allele (A149P) in the British population
148. Hereditary fructose intolerance
149. Clinical mitochondrial genetics
150. Mitochondrial respiratory chain disorders and the liver
151. Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase deficiency with neonatal-onset hepatic failure and encephalopathy
152. Microvesicular steatosis, hemosiderosis and rapid development of liver cirrhosis in a patient with Pearson's syndrome
153. Valproic acid hepatic fatalities. III. U.S. experience since 1986
154. Valproate-induced liver failure in one of two siblings with Alpers disease
155. Progressive infantile poliodystrophy (Alpers' disease) with a defect in citric acid cycle activity in liver and fibroblasts
156. Progressive poliodystrophy (Alpers' disease) with a defect in cytochrome aa3 in muscle: A report of two unrelated patients
157. Inappropriate liver transplantation in a child with Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced acute liver failure
158. Orthotopic liver transplantation with poor neurologic outcome in valproate-associated liver failure: A need for critical risk-benefit appraisal in the use of valproate
159. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure
160. Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: Review of valproate hepatotoxicity in adults
161. Medium chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicity
162. Partial N-acetyl-glutamate synthetase deficiency masquerading as a valproic acid-induced Reye-like syndrome
163. Alpers progressive infantile neuronal poliodystrophy: An acute neonatal form with findings of the fetal akinesia syndrome
164. Alpers' syndrome presenting with seizures and multiple stroke-like episodes in a 17-year-old male
165. Fatal deterioration of neurological disease after orthotopic liver transplantation for valproic acid-induced liver damage
166. Molecular mechanisms in mitochondrial DNA depletion syndrome
167. Mitochondrial DNA depletion in children
168. Depletion of mitochondrial DNA associated with infantile cholestasis and progressive liver fibrosis
169. Low levels of mitochondrial transcription factor A in mitochondrial DNA depletion
170. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy
171. Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency with the G1528C mutation: Clinical presentation of thirteen patients
172. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and early-onset liver cirrhosis in two siblings
173. Mitochondrial respiratory chain complex I deficiency with clinical and biochemical features of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency
174. Secondary respiratory chain defect in a boy with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: Possible diagnostic pitfalls
175. Liver disease in pregnancy and fetal fatty acid oxidation defects
176. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women
177. A broad spectrum of clinical presentations in congenital disorders of glycosylation I: A series of 26 cases
178. Congenital hepatic fibrosis in 3 siblings with phosphomannose isomerase deficiency
179. Phosphomannose isomerase deficiency as a cause of congenital hepatic fibrosis and protein-losing enteropathy
180. Phosphomannose isomerase deficiency: A carbohydrate-deficient glycoprotein syndrome with hepatic-intestinal presentation
181. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy
182. Budd-Chiari syndrome associated with coagulation abnormalities in a child with carbohydrate deficient glycoprotein syndrome type Ix
183. Structure and chemistry of the copper chaperone proteins
184. The copper chaperone Atox1 in canine copper toxicosis in Bedlington terriers
185. Interaction of the copper chaperone HAH1 with the Wilson disease protein is essential for copper homeostasis
186. Structure, expression, and chromosomal localization of the mouse Atoxl gene
187. The copper chaperone for superoxide dismutase
188. The copper chaperone CCS directly interacts with copper/zinc superoxide dismutase
189. The copper chaperone CCS is abundant in neurons and astrocytes in human and rodent brain
190. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase
191. Chromosomal localization of CCS, the copper chaperone for Cu/Zn superoxide dismutase
192. Molecular cloning and characterization of a copper chaperone for copper/zinc superoxide dismutase from the rat
193. The mitochondrial copper metallochaperone Cox17 exists as an oligomeric, polycopper complex
194. Characterization and localization of human COX17, a gene involved in mitochondrial copper transport
195. Mutational analysis of the mitochondrial copper metallochaperone Cox17
196. Isolation of a cDNA encoding the human homolog of COX17, a yeast gene essential for mitochondrial copper recruitment
197. Physiologic function of the Wilson disease gene product, ATP7B
198. Copper-dependent trafficking of Wilson disease mutant ATP7B proteins
199. Copper-induced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion
200. Prevention of Wilson's disease in asymptomatic patients
201. Copper toxicity affects proliferation and viability of human hepatoma cells (HepG2 line)
202. Susceptibility of North Ronaldsay sheep to copper from cupric oxide needles
203. Copper poisoning in sheep from North Ronaldsay maintained on a diet of terrestrial herbage
204. An animal model for copper-associated cirrhosis in infancy
205. Retrorsine in breast milk influences copper handling in suckling rat pups
206. Wilson's disease coexisting with viral hepatitis type C: A case report with histological and ultrastructural studies of the liver
207. Fulminant hepatic failure resulting from coexistent Wilson's disease and hepatitis E
208. Toxic milk, a new mutation affecting cooper metabolism in the mouse
209. The toxic milk mutation, tx, which results in a condition resembling Wilson disease in humans, is linked to mouse chromosome 8
210. The toxic milk mouse is a murine model of Wilson disease
211. Defective localization of the Wilson disease protein (ATP7B) in the mammary gland of the toxic milk mouse and the effects of copper supplementation
212. Functional studies on the Wilson copper P-type ATPase and toxic milk mouse mutant
213. The Long-Evans cinnamon (LEC) rat and copper metabolism
214. Responsible gene for hepatitis of the LEC rat (hts) is the homolog of the human Wilson's disease (WD) gene
215. The LEC rat has a deletion in the copper transporting ATPase gene homologous to the Wilson disease gene
216. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis
217. Correction of liver disease following transplantation of normal rat hepatocytes into Long-Evans cinnamon rats modeling Wilson's disease
218. Role of copper in Indian childhood cirrhosis
219. Long term survival in Indian childhood cirrhosis treated with D-penicillamine
220. Reversal of Indian childhood cirrhosis by D-penicillamine therapy
221. The prevention of Indian childhood cirrhosis
222. Uptake of copper from brass vessels by bovine milk and its relevance to Indian childhood cirrhosis
223. Indian childhood cirrhosis and Tyrolean childhood cirrhosis. Disorders of a copper transport gene?
224. Indian childhood cirrhosis-like disease in a Japanese boy undergoing liver transplantation
225. Non-Indian childhood cirrhosis
226. Late manifestation of Indian childhood cirrhosis in a 3-year-old German girl
227. Indian childhood cirrhosis in an American child
228. First description of "Indian childhood cirrhosis" in a non-Indian infant in Europe
229. Nutritional copper intoxication in three German infants with severe liver cell damage (features of Indian childhood cirrhosis)
230. Copper storage disease of the liver and chronic dietary copper intoxication in two further German infants mimicking Indian childhood cirrhosis
231. Copper-associated childhood cirrhosis
232. Normal metallothionein synthesis in fibroblasts obtained from children with Indian childhood cirrhosis or copper-associated childhood cirrhosis
233. Hepatic iron storage in very low birthweight infants after multiple blood transfusions
234. Neonatal hemochromatosis: Outcomes of pharmacologic and surgical therapies
235. Neonatal hemochromatosis
236. Rapid development of hepatocellular siderosis after liver transplantation for neonatal hemochromatosis
237. Multiple malformations in neonatal hemochromatosis
238. Neonatal hemochromatosis
239. Fetal liver disease may precede extrahepatic siderosis in neonatal hemochromatosis
240. Familial neonatal hemochromatosis with survival
241. Delta 4-3-oxosteroid 5 heta-reductase deficiency causing neonatal liver failure and hemochromatosis
242. Progressive familial intrahepatic cholestasis. Genetic basis and treatment
243. Intrahepatic cholestasis: Order out of chaos
244. Identification of a new inborn error in bile acid synthesis: Mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease
245. Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids
246. Lack of 3 heta-hydroxy-delta 5-C27-steroid dehydrogenase/isomerase in fibroblasts from a child with urinary excretion of 3 beta-hydroxy-delta 5-bile acids. A new inborn error of metabolism
247. The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis
248. Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis
249. Cloning and expression of cDNA of human delta 4-3-oxosteroid 5 beta-reductase and substrate specificity of the expressed enzyme
250. Clinical and biochemical findings in progressive familial intrahepatic cholestasis
251. Genetic basis of progressive familial intrahepatic cholestasis
252. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis
253. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis
254. Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24
255. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): Evidence for heterogeneity
256. Mapping of a locus for progressive familial intrahepatic cholestasis (Byler disease) to 18q21-q122, the benign recurrent intrahepatic cholestasis region
257. Etiological factors in neonatal cholestasis
258. Clinical aspects on neonatal cholestasis based on observations at a Swedish tertiary referral centre
259. The wide spectrum of multidrug resistance 3 deficiency: From neonatal cholestasis to cirrhosis of adulthood
260. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: Evidence for a defect in protein trafficking
261. Bile acids and hepatocyte apoptosis: Living/leaving life in the Fas lane
262. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition
263. Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation